Ambuja Cements (AMBUJACEM) — deviation variation

Ambuja Cements Limited reported no deviations or variations in the use of proceeds from its preferential issue of equity shares for Q2 FY2025-26 (ended September 30, 2025). The company raised ₹15,000.046 crores across two tranches in March-April 2024 for capital expenditures, de-bottlenecking, logistics infrastructure, and general corporate purposes. As of June 30, 2025, ₹14,795.1 crores had been utilized with nil deviation, confirmed by the Audit Committee.

📄 View Original Announcement (PDF)

📊 Stock Analysis — AMBUJACEM ✨ Ask AI About This

About Ambuja Cements Limited (AMBUJACEM)

Construction Materials · Cement & Cement Products · Listed on NSE

Market Cap: ₹1,07,215.34 Cr P/E: 23.3 ROE: 7.7% ROCE: 4.6%

View full AMBUJACEM stock details →

📡 Get AI alerts when AMBUJACEM files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track AMBUJACEM — Free

💡 Ask AI about this filing

"How does this deviation variation affect Ambuja Cements Limited's outlook?" "What did Ambuja Cements Limited announce on 3 November 2025?" "Is this positive or negative for AMBUJACEM?"

Ask AI Free →

📊 More AMBUJACEM filings

See all AMBUJACEM filings →

🔥 Also filed on 3 November 2025

BHARTIARTL Bharti Airtel Limited Financial Results BRITANNIA Britannia Industries Limited Financial Results BAJAJFINSV Bajaj Finserv Limited Financial Results BEL Bharat Electronics Limited Financial Results ULTRACEMCO UltraTech Cement Limited Corporate Action CANBK Canara Bank Financial Results

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when AMBUJACEM files new disclosures

Track AMBUJACEM filings, board meetings, and corporate actions. Free email alerts at 5 PM.